Evidence map›Paper›PMID 35894603›Full record

ArticleJournal of virology2022

Adaptation to a Multiplex Bead Assay and Seroprevalence to Rift Valley Fever N Protein: Nampula Province, Mozambique, 2013-2014.

Eric Rogier, Mateusz Plucinski, Baltazar Candrinho, Delynn M Moss, Aridth Gibbons, James Colborn, Jeffrey Higgins, Geraldo Chambe, Joao Muchanga, Olinda Muguande and 8 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Eric RogierDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.ORCID 0000-0001-7375-8304
Mateusz PlucinskiDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.ORCID 0000-0002-7322-4625
Baltazar CandrinhoNational Malaria Control Program, Ministry of Health, Maputo, Mozambique, Africa.
Delynn M MossDivision of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Aridth GibbonsDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
James ColbornClinton Health Access Initiative, Boston, Massachusetts, USA.
Jeffrey HigginsOffice of Innovation and Analytics, Centers for Disease Control and Preventiongrid.416738.f/Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, USA.
Geraldo ChambeMozambique Field Epidemiology and Laboratory Training Program, Maputo, Mozambique, Africa.
Joao MuchangaMozambique Field Epidemiology and Laboratory Training Program, Maputo, Mozambique, Africa.
Olinda MuguandeNational Malaria Control Program, Ministry of Health, Maputo, Mozambique, Africa.
Graca MatsinheNational Malaria Control Program, Ministry of Health, Maputo, Mozambique, Africa.
Guidion MatheNational Malaria Control Program, Ministry of Health, Maputo, Mozambique, Africa.
Timothy DoyleField Epidemiology and Laboratory Training Program, Centers for Disease Control and Preventiongrid.416738.f, Maputo, Mozambique, Africa.
Rose ZulligerDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Abu SaifodineUS President's Malaria Initiative, United States Agency for International Developmentgrid.420285.9, Maputo, Mozambique, Africa.
Joel M MontgomeryDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
John D KlenaDivision of High-Consequence Pathogens and Pathology, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Jeffrey W PriestDivision of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Centers for Disease Control and Prevention · USMinistry of Health · MZNational Directorate of Geology · MZClinton Health Access Initiative · USUnited States Agency for International Development · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rift Valley fever virus (RVFV) is endemic in sub-Saharan Africa (SSA), with outbreaks reported in the Arabian Peninsula and throughout SSA. The natural reservoir for RVFV are ruminants, with livestock populations exceeding 50% exposure rates in some areas of SSA. Transmission to humans can occur through exposure to infected livestock products or multiple species of mosquito vectors. In 2013 and 2014, cross-sectional surveys occurred in two districts of Nacala-a-Velha and Mecubúri in northern Mozambique, and participants provided blood samples for later serological assays. IgG against the N protein of RVFV was detected through multiplex bead assay (MBA). Of the 2,278 persons enrolled between the two surveys and study sites, 181 (7.9%, 95% confidence interval (CI): 6.9%-9.1%) were found to be IgG seropositive with increasing seroprevalence with older age and significantly higher seroprevalence in Nacala-a-Velha (10.5%, 8.8%-12.5%) versus Mecubúri (5.7%, 4.5%-7.1%). Seroprevalence estimates were not significantly different between the 2013 and 2014 surveys. Significant spatial clustering of IgG positive persons were consistent among surveys and within the two districts, pointing toward the consistency of serology data for making population-level assumptions regarding RVFV seroprevalence. A subset of persons (

Indexed as

Rift Valley FeverRift Valley fever virusAgedAged, 80 and overAnimalsAntibodies, ViralCross-Sectional StudiesFemaleHumansImmunoglobulin GLivestockMaleMicrobiological TechniquesMozambiqueNucleocapsid ProteinsSeroepidemiologic StudiesAntibodies, ViralImmunoglobulin GNucleocapsid ProteinsIgGMozambiqueRift Valley fever virusrisk factorsseroconversionserologyseroprevalence

Identifiers

PMID35894603
PMCPMC9400480
OpenAlexW4288067943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.